Eyenovia, Inc.

← The SEC Ephemeris: the whole map

Eyenovia, Inc. MYDCOMBI

In the graph: all 1 documents (5 pages).

Application: NDA 215352
Ticker: Eyenovia, Inc.
Product: MYDCOMBI
Disease area: Not yet classified
Response path: Not yet classified
Complete Response Letters: October 22, 2021

From FDA letters and SEC filings. Not investment or medical advice.

Not yet classified

Cyclomedica Australia Pty Ltd. Technegas™ Technetium Tc-99m carbon aerosol
Daiichi Sankyo, Inc. this action below
DBV Technologies S.A. Peanut Allergen Extract manufactured at your location
Defender Pharmaceuticals, Inc scopolamine
Delcath Systems, Incorporated Melblez
Disc Medicine, Inc. bitopertin
Dow Pharmaceutical Sciences, Inc. halobetasol propionate
Dr. Reddy’s Laboratories, Inc. AVT03
DURECT Corporation POSIMIR
Eagle Pharmaceuticals, Inc. Fulvestrant
ELC Group Lutrate®
Elevar Therapeutics, Inc. rivoceranib
Eli Lilly and Company lebrikizumab
EMD Serono, Inc. cladribine
Emory Partners, LLC Dyanavel XR
Esteve Pharmaceuticals, S.A. celecoxib
Evergreen Theragnostics, Inc.
Evofem, Inc. Amphora
Evoke Pharma, Inc. Gimoti
Evolus, Inc. otulinum toxin Type A
Eyenovia, Inc. MYDCOMBI
Fabre-Kramer Pharmaceuticals, Inc. Gepirone Hydrochloride Extended Release
The Feinstein Institute for Medical Research Fluorodopa F
Fennec Pharmaceuticals, Inc. PEDMARK
Fera Pharmaceuticals, LLC Avaclyr
Ferring Pharmaceuticals Inc. progesterone
Fidelity BioPharma Co. Ontralfy
Fresenius Kabi USA, LLC MSB11456
Galderma R&D, LLC this action
Galephar Pharmaceutical Research Inc. Legubeti
Gan & Lee Pharmaceuticals
Genentech, Incorporated XOFLUZA
Genzyme Corporation tolebrutinib
Gilead Sciences, Inc. lenacapavir
GlaxoSmithKline LLC Exdensur lepemokimab-ulaa)
Glenmark Pharmaceuticals, Inc. GSP
Grace Therapeutics U.S., Inc. nimodipine
Green Cross Corporation immune globulin
Heritage Pharmaceuticals Inc. d/b/a/ Avet Pharmaceuticals Inc. the following drug product: > Atazanavir Sulfate

All 283 on the full map →

Group by

Build queue · replay at pipeline speed